Xeljanz XR Alternatives Compared
| Xeljanz XR (tofacitinib) | Cosentyx (secukinumab) | Humira (adalimumab) |
|
|---|
| Xeljanz XR (tofacitinib) | Cosentyx (secukinumab) | Humira (adalimumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Ankylosing Spondylitis, Rheumatoid Arthritis, Ulcerative Colitis, Psoriatic Arthritis. Xeljanz XR may also be used for purposes not listed in this medication guide. |
Prescription only
Cosentyx may be used to treat plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, hidradenitis suppurativa (HS), and some other conditions. After an initial loading dose, Cosentyx can be... View more |
Prescription only
Humira is a TNF-alfa inhibitor that may be used to treat a wide range of different inflammatory conditions, such as Rheumatoid Arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, and... View more |
Related suggestions Ankylosing Spondylitis
|
|||||||||||||||||||||||
| More about (tofacitinib) | More about Cosentyx (secukinumab) | More about Humira (adalimumab) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Xeljanz XR has an average rating of 6.4 out of 10 from a total of 17 ratings on Drugs.com. 59% of reviewers reported a positive effect, while 35% reported a negative effect. |
Cosentyx has an average rating of 6.3 out of 10 from a total of 253 ratings on Drugs.com. 52% of reviewers reported a positive effect, while 30% reported a negative effect. |
Humira has an average rating of 6.4 out of 10 from a total of 703 ratings on Drugs.com. 55% of reviewers reported a positive effect, while 30% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Xeljanz XR side effects |
View all Cosentyx side effects |
View all Humira side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Xeljanz XR prices |
View all Cosentyx prices |
View all Humira prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other tofacitinib brands include: Xeljanz, Xeljanz Oral Solution |
N/A |
Other adalimumab brands include: Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry View more | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
3 hours |
744 hours |
480 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 675 drugs are known to interact with Xeljanz XR:
|
A total of 252 drugs are known to interact with Cosentyx:
|
A total of 555 drugs are known to interact with Humira:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
January 21, 2015 |
December 31, 2002 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
|
N/A |
||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
|
N/A |
||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Otezla
Otezla (apremilast) is used to treat plaque psoriasis, psoriatic arthritis, and oral ulcers ...
Skyrizi
Skyrizi (risankizumab) is used to treat plaque psoriasis, psoriatic arthritis, ulcerative colitis ...
Entyvio
Entyvio (vedolizumab) is used to treat ulcerative colitis (UC) and Crohn's disease, reducing ...
Omvoh
Omvoh is used to treat moderate to severe ulcerative colitis or Crohn's disease in adults. This ...
Stelara
Stelara (ustekinumab) is used to treat Crohn's disease, ulcerative colitis, plaque psoriasis, and ...
Cosentyx
Cosentyx (secukinumab) is used to treat plaque psoriasis, psoriatic arthritis, ankylosing ...
Humira
Humira is a tumor necrosis factor blocker used to treat many inflammatory conditions in adults ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Enbrel
Enbrel is used to treat rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Learn about ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.